At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Denosumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·interventional·Posted May 4, 2016·Updated Aug 11, 2017
In Brief
A Phase 4 clinical trial evaluating Denosumab and Placebo for Bone Resorption. Completed, enrolled 60 participants.
Detailed Summary
This study evaluates the effect of Denosumab in decreasing the periprosthetic bone resorption after Total Knee Arthroplasty compared to placebo in 60 patients (30 placebo and 30 Denosumab) within a year after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Resorption
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
Primary CompletionJan 2014
Study CompletionJun 2015
First PostedMay 2016
TodayJul 2026
First PostedMay 4, 2016
Enrollment StartJan 1, 2013
Primary CompletionJan 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.2 years ago
Interventions
Denosumabdrug
Denosumab treatment one year after surgery
Placebodrug
Serum one year after surgery